Syndax Pharmaceuticals Net Worth
Syndax Pharmaceuticals Net Worth Breakdown | SNDX |
Syndax Pharmaceuticals Net Worth Analysis
Syndax Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Syndax Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Syndax Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Syndax Pharmaceuticals' net worth analysis. One common approach is to calculate Syndax Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Syndax Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Syndax Pharmaceuticals' net worth. This approach calculates the present value of Syndax Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Syndax Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Syndax Pharmaceuticals' net worth. This involves comparing Syndax Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Syndax Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Syndax Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Syndax Pharmaceuticals' net worth research are outlined below:
| Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Syndax Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (209.36 M) with profit before overhead, payroll, taxes, and interest of 139.71 M. | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (160.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Syndax Pharmaceuticals Stock Price Expected to Rise, Citigroup Analyst Says |
Syndax Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Syndax Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Syndax Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Syndax Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Syndax Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syndax Pharmaceuticals backward and forwards among themselves. Syndax Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syndax Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Orbimed Advisors, Llc | 2024-06-30 | 1.9 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.8 M | Franklin Resources Inc | 2024-09-30 | 1.8 M | Stempoint Capital Lp | 2024-09-30 | 1.7 M | Woodline Partners Lp | 2024-06-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | First Turn Management Llc | 2024-09-30 | 1.2 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 7.9 M | Wellington Management Company Llp | 2024-06-30 | 7.3 M |
Follow Syndax Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.43 B.Market Cap |
|
Project Syndax Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.38) | (0.40) |
When accessing Syndax Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Syndax Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Syndax Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Check Syndax Pharmaceuticals' Beneish M Score to see the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Evaluate Syndax Pharmaceuticals' management efficiency
Syndax Pharmaceuticals has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8188) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.36 in 2024. Return On Capital Employed is likely to drop to -0.44 in 2024. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 33.6 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 646 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.88 | 8.27 | |
| Tangible Book Value Per Share | 7.88 | 8.27 | |
| Enterprise Value Over EBITDA | (5.34) | (5.60) | |
| Price Book Value Ratio | 2.74 | 2.88 | |
| Enterprise Value Multiple | (5.34) | (5.60) | |
| Price Fair Value | 2.74 | 2.88 | |
| Enterprise Value | 1.2 B | 1.3 B |
Management at Syndax Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 63.9058 | Revenue 16 M | Quarterly Revenue Growth 332.974 | Revenue Per Share 0.195 | Return On Equity (0.82) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gallagher Neil over two months ago Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3 | ||
Jarrett Jennifer over three months ago Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over six months ago Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3 | ||
Briggs Morrison over six months ago Acquisition by Briggs Morrison of 52855 shares of Syndax Pharmaceuticals at 8.77 subject to Rule 16b-3 | ||
Dennis Podlesak over six months ago Acquisition by Dennis Podlesak of 34000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over a year ago Exercise or conversion by Peter Ordentlich of 7572 shares of Syndax Pharmaceuticals subject to Rule 16b-3 |
Syndax Pharmaceuticals Corporate Filings
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 17th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 16th of May 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Syndax Pharmaceuticals Earnings per Share Projection vs Actual
Syndax Pharmaceuticals Corporate Management
| Briggs MD | Head Pres | Profile | |
| Steven Closter | Chief Officer | Profile | |
| Michael MBA | CEO Director | Profile | |
| Steve Sabus | Chief Officer | Profile | |
| Joseph MD | Member Officer | Profile | |
| Ronald Evans | Advisor CoFounder | Profile | |
| Sharon Klahre | Vice Communications | Profile |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.